南華生物(000504.SZ):控股股東擬公開徵集協議轉讓7%的股份
格隆匯6月15日丨南華生物(000504.SZ)公佈,2021年6月15日,公司的控股股東湖南省財信產業基金管理有限公司(“財信產業基金”)的《關於公開徵集協議轉讓不超過7%貴司股份的函》,主要內容如下:
“為引入未來發展重要戰略資源,進一步優化股份股權結構,提升貴司發展潛力,推動貴司可持續發展,根據《上市公司國有股權監督管理辦法》(國務院國有資產監督管理委員會、財政部、中國證券監督管理委員會令第36號)等有關規定,我司擬通過公開徵集轉讓方式協議轉讓其持有的貴司2181.0173萬股股份,佔貴司總股本的7.00%,本次轉讓完成後我司仍為第一大股東。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.